Loading clinical trials...
Loading clinical trials...
Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Neoadjuvant Cisplatin, nab-paclitaxel
Adjuvant Cisplatin,nab-paclitaxel
+1 more
Locations
9
United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory - Winship Cancer Institute
Atlanta, Georgia, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
Ochsner Cancer Institute
New Orleans, Louisiana, United States
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Rex Cancer Center and Rex of Wakefield
Raleigh, North Carolina, United States
Start Date
January 1, 2015
Primary Completion Date
June 1, 2016
Completion Date
June 1, 2016
Last Updated
May 11, 2017
NCT01629498
NCT02495896
NCT04062708
NCT01993810
NCT02621398
NCT03916419
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions